Sino Biopharmaceutical Limited

1177

KYG8167W1380

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:09:09 2024-04-25 am EDT			5-day change	1st Jan Change
2.74 ^HKD	+2.24%		+12.76%	-21.04%

Apr. 25	Sino Biopharm Completes Phase I Study of Hepatitis B Drug	MT
Apr. 22	Lull in Geopolitical Tensions Lifts Asian Stock Markets	MT

HanchorBio Inc. announced that it has received $10 million in funding from Zero2IPO Ventures, Yuexiu Industrial Fund, Sino Biopharmaceutical Limited, Yuan-sheng Suzhou Industrial Park Venture Capital Management Co., Ltd., Panacea Venture Management Co., Ltd.

September 08, 2022

HanchorBio Inc. announced that it has received $10,000,000 in funding led by Sino Biopharmaceutical Limited on September 9, 2022. The transaction included participation from Zero2IPO Ventures, Yuexiu Industrial Fund, Yuan-sheng Suzhou Industrial Park Venture Capital Management Co., Ltd., and Panacea Venture Management Co., Ltd.

Latest news about Sino Biopharmaceutical Limited

Sino Biopharm Completes Phase I Study of Hepatitis B Drug	Apr. 25	MT
Lull in Geopolitical Tensions Lifts Asian Stock Markets	Apr. 22	MT
Hong Kong shares jump on policy support; China slips	Apr. 22	RE
Hong Kong shares jump 1.5% on policy support; China slips	Apr. 22	RE
Sino Biopharmaceutical Reaches Primary Endpoint for Clinical Research of Myelofibrosis Drug	Apr. 19	MT
Sino Biopharmaceutical Limited Announces Category 1 Innovative Drug Rovadicitinib Obtained Positive Results in Key Clinical Research for Registration	Apr. 18	CI
Sino Biopharm EBT Buys Back HK$12 Million Worth of Shares	Apr. 17	MT
Sino Biopharmaceutical Presents Cancer Drug's Phase-II Clinical Trial Results at AACR 2024	Apr. 10	MT
Sino Biopharmaceutical Trustee Repurchases Shares	Apr. 08	MT
Sino Biopharmaceutical to Develop Boehringer Ingelheim's Cancer Treatments in China	Apr. 08	MT
Sino Biopharmaceutical Limited Enters into Strategic Partnership with Boehringer Ingelheim on Innovative Oncology Portfolio in China	Apr. 07	CI
Sino Biopharmaceutical's Attributable Profit Drops 8.3% in 2023	Mar. 29	MT
Sino Biopharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 5 July 2024	Mar. 28	CI
Sino Biopharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Sino Biopharmaceutical's Diagnostic Agent Injection Gets Marketing Nod in China	Mar. 24	MT
Sino Biopharmaceutical Limited Announces Approval for Marketing of Iopromide Injection	Mar. 24	CI
Sino Biopharmaceutical's Developing Two Drugs for MASH	Mar. 15	MT
Nomura Adjusts Sino Biopharmaceutical’s Price Target to HK$6.16 From HK$6.63, Keeps at Buy	Mar. 15	MT
Sino Biopharmaceutical Limited Provides Update on Development Progress of Mash Products "Lanifibranor" and "TQA2225"	Mar. 15	CI
Sino Biopharmaceutical to Present Cancer Drug Phase II Trial Findings at 2024 AACR	Mar. 14	MT
Sino Biopharmaceutical Limited Announces Latest Results of Phase II Clinical Study of KRAS G12C Inhibitor Garsorasib Tablet	Mar. 13	CI
Hong Kong Shares Slump Amid Chinese Growth Concerns	Mar. 05	MT
Sino Biopharmaceutical Limited Announces Acceptance of the New Indication Application for Marketing of Anlotinib Hydrochloride Capsules and Anti Pd-L1 Benmelstobart	Feb. 28	CI
Sino Biopharmaceutical's Anti-Cancer Drug Under Priority Review in China	Feb. 07	MT
Sino Biopharm Units Sell 67% Stake in Pharmaceutical Company	Feb. 06	MT

Chart Sino Biopharmaceutical Limited

Duration

Period

More charts

Company Profile

Sino Biopharmaceutical Limited specialises in the development, manufacture and marketing of biopharmaceutical products primarily for the treatment of cancer, ophthalmia, hepatitis, orthopedic diseases and respiratory disorders. Net sales break down by category of products as follows: - chemical medicine products and biopharmaceutical drugs (97.6%); - other (2.4%).

Sector

Pharmaceuticals

Calendar

2024-06-10 - Final dividend

Related indices

HONG KONG HANG SENG

More about the company

Income Statement Evolution

More financial data

Ratings for Sino Biopharmaceutical Limited

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.536 CNY

Average target price

4.32 CNY

Spread / Average Target

+70.37%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SINO BIOPHARMACEUTICAL LIMITED	-21.04%	6.27B
NOVO NORDISK A/S	+24.17%	562B
JOHNSON & JOHNSON	-6.33%	358B
MERCK & CO., INC.	+19.90%	322B
ABBVIE INC.	+7.95%	297B
ASTRAZENECA PLC	+13.45%	219B
NOVARTIS AG	+6.04%	199B
ROCHE HOLDING AG	-10.51%	196B
PFIZER, INC.	-12.26%	149B
AMGEN INC.	-6.47%	146B

Other Pharmaceuticals

Sino Biopharmaceutical Limited

Equities

1177

KYG8167W1380

Pharmaceuticals

HanchorBio Inc. announced that it has received $10 million in funding from Zero2IPO Ventures, Yuexiu Industrial Fund, Sino Biopharmaceutical Limited, Yuan-sheng Suzhou Industrial Park Venture Capital Management Co., Ltd., Panacea Venture Management Co., Ltd.

EPS Revisions